Fennec Announces FDA Filing Acceptance for Ototoxicity Drug, Pedmark

PEDMARK is said to be an investigational drug for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to <18 years of age with localized, non-metastatic, solid tumors.